Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Xetra  >  Fresenius Medical Care AG & Co. KGaA    FME   DE0005785802

FRESENIUS MEDICAL CARE AG & CO. KGAA

(FME)
  Report
SummaryQuotesChartsNewsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Fresenius Medical says fourth-quarter operating profit up 3%

02/19/2020 | 06:42pm EST
FILE PHOTO: Fresenius headquarters in in Bad Homburg

Germany's Fresenius Medical Care on Wednesday said quarterly adjusted operating income edged 3% higher as growth in dialysis services and products was partly offset by a negative adjustment for accounts receivable in a legal dispute in North America.

Fourth-quarter earnings before interest and tax, adjusted for special items, advanced to 655 million euros ($707 million), the group said in a statement, coming in below a median analyst estimate of 689 million euros, according to a company-provided poll.

The kidney dialysis provider, controlled by diversified healthcare group Fresenius SE, reaffirmed a guidance for 2020 revenue and net income to grow at a mid- to high single-digit rate in 2020, when measured without currency swings and excluding special items.

The guidance is based on the adjusted results for 2019, including the acquisition of home dialysis company NxStage, it added.

The group added it was too early to quantify the impact of the coronavirus outbreak in China on its Asia-Pacific operations and that its priority was to continue treating its dialysis patients as well as employee safety.

Asia accounted for 11% of its total quarterly revenue of 4.58 billion euros.

By Ludwig Burger


© Reuters 2020
Stocks mentioned in the article
ChangeLast1st jan.
AT HOME GROUP INC. 1.54% 19.14 Delayed Quote.248.00%
FRESENIUS MEDICAL CARE AG & CO. KGAA 0.83% 70.82 Delayed Quote.7.37%
FRESENIUS SE & CO. KGAA 1.06% 38.07 Delayed Quote.-24.13%
JUST GROUP PLC 0.79% 57.65 Delayed Quote.-27.03%
WILL GROUP, INC. 0.91% 999 End-of-day quote.-20.21%
All news about FRESENIUS MEDICAL CARE AG & CO. KGAA
11/27Swiss drugmaker Vifor had bid interest but talks halted - sources
RE
11/24FRESENIUS SE : UBS remains Neutral
MD
11/19FMC FRESENIUS MEDICAL CARE AG & CO K : RBC reiterates its Neutral rating
MD
11/19FMC FRESENIUS MEDICAL CARE AG & CO K : Bernstein reiterates its Neutral rating
MD
11/19FRESENIUS SE : Bernstein reiterates its Buy rating
MD
11/17FMC FRESENIUS MEDICAL CARE AG & CO K : Jefferies reiterates its Neutral rating
MD
11/16FRESENIUS MEDICAL CARE : included for 11th time in Dow Jones Sustainability Inde..
PU
11/13FRESENIUS SE : Receives a Buy rating from Bernstein
MD
11/12FMC FRESENIUS MEDICAL CARE AG & CO K : Gets a Neutral rating from Bernstein
MD
11/11FRESENIUS MEDICAL CARE AG & CO. KGAA : Notification and public disclosure of tra..
EQ
More news
Financials (USD)
Sales 2020 21 231 M - -
Net income 2020 1 532 M - -
Net Debt 2020 15 175 M - -
P/E ratio 2020 16,3x
Yield 2020 1,65%
Capitalization 24 809 M 24 795 M -
EV / Sales 2020 1,88x
EV / Sales 2021 1,74x
Nbr of Employees 126 463
Free-Float 65,1%
Chart FRESENIUS MEDICAL CARE AG & CO. KGAA
Duration : Period :
Fresenius Medical Care AG & Co. KGaA Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends FRESENIUS MEDICAL CARE AG & CO. KGAA
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 21
Average target price 95,34 $
Last Close Price 84,72 $
Spread / Highest target 32,3%
Spread / Average Target 12,5%
Spread / Lowest Target -25,0%
EPS Revisions
Managers
NameTitle
Rice Powell Chairman-Management Board
Dieter Schenk Chairman-Supervisory Board
Helen Giza Chief Financial Officer
Olaf Schermeier CEO-Global Research & Development
Franklin W. Maddux Global Chief Medical Officer